Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.43 |
| ▸ | LSS | P48449 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804405 | 1.00 | SIGMAR1 (0.45) | SIGMAR1TMEM97LSSCHRM2CHRM1 | |
| SCHEMBL7204007 | 0.90 | SIGMAR1 (0.42) | SIGMAR1TMEM97LSSCCR5L3MBTL1 | |
| SCHEMBL7204010 | 0.90 | SIGMAR1 (0.42) | SIGMAR1TMEM97LSSCCR5L3MBTL1 | |
| SCHEMBL4806887 | 0.90 | SIGMAR1 (0.42) | SIGMAR1TMEM97LSSCCR5L3MBTL1 | |
| SCHEMBL4806879 | 0.90 | SIGMAR1 (0.42) | SIGMAR1TMEM97LSSCCR5L3MBTL1 | |
| SCHEMBL4806079 | 0.89 | SIGMAR1 (0.45) | SIGMAR1TMEM97LSSCHRM2CHRM1 | |
| SCHEMBL4806072 | 0.89 | SIGMAR1 (0.45) | SIGMAR1TMEM97LSSCHRM2CHRM1 | |
| SCHEMBL4805748 | 0.89 | SIGMAR1 (0.41) | SIGMAR1TMEM97LSSCCR5L3MBTL1 | |
| SCHEMBL4805756 | 0.89 | SIGMAR1 (0.41) | SIGMAR1TMEM97LSSCCR5L3MBTL1 | |
| SCHEMBL4809055 | 0.89 | CCR5 (0.46) | SIGMAR1TMEM97LSSCCR5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100455566-C | Novel derivatives of aminocyclohexane | HOFFMANN LA ROCHE (CH) | 2009-01-28 | — | — | CN | disclosed |
| EP-1311475-B1 | AMINOCYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-08-06 | — | — | EP | disclosed |
| US-7335687-B2 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | ACKERMANN JEAN (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6858651-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-02-22 | — | — | US | disclosed |
| CN-1468214-A | Novel derivatives of aminocyclohexane | - | 2004-01-14 | — | — | CN | disclosed |
| EP-1311475-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2002014267-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | SIGMAR1 4687/4885TMEM97 2403/4885LSS 2/4885 |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | SIGMAR1 4687/4885TMEM97 2403/4885LSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.